Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening.
BACKGROUND
In view of the current widespread use of and reliance on a single schistosomicide, praziquantel, there is a pressing need to discover and develop alternative drugs for schistosomiasis. One approach to this is to develop High Throughput in vitro whole organism screens (HTS) to identify hits amongst large compound libraries.


RESULTS
We have been carrying out low throughput (24-well plate) in vitro testing based on microscopic evaluation of killing of ex-vivo adult S. mansoni worms using selected compound collections mainly provided through the WHO-TDR Helminth Drug Initiative. To increase throughput, we introduced a similar but higher throughput 96-well primary in vitro assay using the schistosomula stage which can be readily produced in vitro in large quantities. In addition to morphological readout of viability we have investigated using fluorometric determination of the reduction of Alamar blue (AB), a redox indicator of enzyme activity widely used in whole organism screening. A panel of 7 known schistosome active compounds including praziquantel, produced diverse effects on larval morphology within 3 days of culture although only two induced marked larval death within 7 days. The AB assay was very effective in detecting these lethal compounds but proved more inconsistent in detecting compounds which damaged but did not kill. The utility of the AB assay in detecting compounds which cause severe morbidity and/or death of schistosomula was confirmed in testing a panel of compounds previously selected in library screening as having activity against the adult worms. Furthermore, in prospective library screening, the AB assay was able to detect all compounds which induced killing and also the majority of compounds designated as hits based on morphological changes.


CONCLUSIONS
We conclude that an HTS combining AB readout and image-based analysis would provide an efficient and stringent primary assay for schistosome drug discovery.
Mansour
Nuha R
NR
Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Bickle
Quentin D
QD
D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D057166:High-Throughput Screening Assays / Q000379:methods; D006801:Humans; D007814:Larva / Q000033:anatomy & histology / Q000187:drug effects; D008853:Microscopy; D010078:Oxazines / Q000378:metabolism; D012547:Schistosoma / Q000033:anatomy & histology / Q000187:drug effects*; D012552:Schistosomiasis / Q000453:epidemiology; D013194:Staining and Labeling; D016019:Survival Analysis; D014966:Xanthenes / Q000378:metabolism
D000871:Anthelmintics; D010078:Oxazines; D014966:Xanthenes; C005843:resazurin